Lack of Association of Variants Previously Associated with Anti-TNF Medication Response in Rheumatoid Arthritis Patients: Results from a Homogeneous Greek Population

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Zervou, Maria I ^a   Myrthianou, Efsevia ^a   Flouri, Irene ^a   Plant, Darren ^b   Chlouverakis, Gregory ^c   Castro Giner, Francesc ^d   Rapsomaniki, Panayiota ^a   Barton, Anne ^b,e   Boumpas, Dimitrios T ^f,g,h   Sidiropoulos, Prodromos ^a   Goulielmos, George N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b Manchester Academic Health Science Centre   (United Kingdom)

^c UNIVERSITY OF CRETE   (Greece)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^h INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; MYELOID DIFFERENTIATION FACTOR 88; STAT4 PROTEIN; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ADULT; AFF3 GENE; ARTICLE; CD226 GENE; CHUK GENE; COHORT ANALYSIS; DAS28; DISEASE MARKER; DISEASE PREDISPOSITION; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; GREECE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYD88 GENE; OUTCOME ASSESSMENT; PTPRC GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOUNDER EFFECT; GENETIC LOCI; GENETIC MARKERS; GREECE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883816559     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074375     Document Type: Article

References (31)

1. McInnes IB, Schett G, (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365: 2205-2219 (Review) doi:10.1056/NEJMra1004965. PubMed: 22150039.
2. NICE. Rheumatoid arthritis-drugs for treatment after failure of a TNF inhibitor. Available: http://guidance.nice.org.uk/TA195.
3. Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343: 1594-1602. doi:10.1056/NEJM200011303432202. PubMed: 11096166.
4. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN, (2004) The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 18: 59-80. doi:10.1016/j.berh.2003.09.010. PubMed: 15123038.
5. Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, et al. (2011) Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 31: 817-833. PubMed: 22037040.
6. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, et al. (2004) The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50: 2750-2756. doi:10.1002/art.20469. PubMed: 15457442.
7. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, et al. (2010) Rheumatoid Arthritis Risk Allele PTPRC Is Also Associated With Response to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheum 62: 1849-1861. PubMed: 20309874.
8. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, et al. (2009) Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68: 69-74. PubMed: 18375541.
9. Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, et al. (2010) Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 69: 1029-1035. doi:10.1136/ard.2009.118406. PubMed: 20444755.
10. Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, et al. (2012) Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 64: 665-670. doi:10.1002/art.33381. PubMed: 21952740.
11. Prajapati R, Plant D, Barton A, (2011) Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 12: 1571-1585 (Review) doi:10.2217/pgs.11.114. PubMed: 22044414.
12. Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, et al. (2011) Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 63: 645-653. doi:10.1002/art.30130. PubMed: 21061259.
13. Barton A, Eyre S, Ke X, Bowes J, Panoutsopoulou K, et al. (2009) Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further panautoimmune susceptibility genes. Hum Mol Genet 18: 2518-2522. doi:10.1093/hmg/ddp177. PubMed: 19359276.
14. Hafler JP, Maier LM, Cooper JD, Plagnol V, Hinks A, et al. (2009) CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 10: 5-10. doi:10.1038/gene.2009.85. PubMed: 18971939.
15. Plant D, Flynn E, Mbarek H, Dieudé P, Cornelis F, et al. (2010) Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis 69: 1548-1553. doi:10.1136/ard.2009.121020. PubMed: 20498205.
16. Kurreeman FA, Padyukov L, Marques RB, Schrodi SJ, Seddighzadeh M, et al. (2007) A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLOS Med 4: e278. doi:10.1371/journal.pmed.0040278. PubMed: 17880261.
17. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, et al. (2007) TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 357: 1199-1209. doi:10.1056/NEJMoa073491. PubMed: 17804836.
18. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, et al. (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357: 977-986. doi:10.1056/NEJMoa073003. PubMed: 17804842.
19. Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, et al. (2001) TRAF1 is a negative regulator of TNF signaling that enhanced TNF signaling in TRAF1-deficient mice. Immunity 15: 647-657. doi:10.1016/S1074-7613(01)00207-2. PubMed: 11672546.
20. Wajant H, Henkler F, Scheurich P, (2001) The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 13: 389-400. doi:10.1016/S0898-6568(01)00160-7. PubMed: 11384837.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
22. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, et al. (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 39: 34-40. doi:10.1002/art.1780390105. PubMed: 8546736.
23. Zervou MI, Sidiropoulos P, Petraki E, Vazgiourakis V, Krasoudaki E, et al. (2008) Association of a TRAF1 and a STAT4 gene polymorphism with increased risk for rheumatoid arthritis in a genetically homogeneous population. Hum Immunol 69: 567-571. doi:10.1016/j.humimm.2008.06.006. PubMed: 18625278.
24. Zervou MI, Goulielmos GN, Castro-Giner F, Tosca AD, Krueger-Krasagakis S, (2009) STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece. Hum Immunol 70: 738-741. doi:10.1016/j.humimm.2009.05.008. PubMed: 19500629.
25. Mantaka A, Goulielmos GN, Koulentaki M, Tsagournis O, Voumvouraki A, et al. (2012) Polymorphisms of genes related to endothelial cells are associated with Primary Biliary Cirrhosis (PBC) patients of Cretan origin. Hum Immunol 73: 829-835. doi:10.1016/j.humimm.2012.05.003. PubMed: 22609442.
26. Patrinos GP, Kollia P, Loutradi-Anagnostou A, Loukopoulos D, Papadakis MN, (1998) The Cretan type of non-deletional hereditary persistence of fetal hemoglobin [A gamma-158C-- >T] results from two independent gene conversion events. Hum Genet 102: 629-634. doi:10.1007/s004390050753. PubMed: 9703422.
27. Spanaki C, Plaitakis A, (2004) Bilineal transmission of Parkinson disease on Crete suggests a complex inheritance. Neurology 62: 815-817. doi:10.1212/01.WNL.0000113720.71387.88. PubMed: 15007141.
28. Apostolakis S, Baritaki S, Krambovitis E, Spandidos DA, (2005) Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population. J Clin Virol 34: 310-314. doi:10.1016/j.jcv.2005.01.010. PubMed: 16286055.
29. Canhão H, Rodrigues A, Santos MJ, Carmona-Fernandes D, Costa J, et al. (2012) TRAF1/C5 locus is associated with response to anti-TNF in rheumatoid arthritis. J Transl Med 10 (Suppl 3) ():: 31. doi:10.1186/1479-5876-10-S2-A31. PubMed: 22369209.
30. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, et al. (2013) Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLOS Genet 9: e1003394. PubMed: 23555300.
31. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, et al. (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106: 135-140. doi:10.1182/blood-2005-01-0341. PubMed: 15790782.